Cresco Labs Financial Data and Market Trends

Cresco Labs has a significant presence in the cannabis industry, with a market capitalization of over $4 billion. This is a testament to the company's growth and expansion in recent years.

Cresco Labs has a strong financial foundation, with a revenue growth rate of 300% in 2020. This rapid growth is a result of the company's strategic partnerships and acquisitions.

In 2020, Cresco Labs generated $143 million in revenue, with a net loss of $44 million. Despite the net loss, the company's revenue growth is a promising sign for its future prospects.

Cresco Labs has a diverse portfolio of brands, including Cresco, Mindy's, and FloraCal. These brands cater to different segments of the cannabis market, from recreational to medical use.

Cresco Labs has a total cash of $146.61 million as of the most recent quarter. This is a significant amount of liquidity that can be used to fund operations, pay off debt, or make strategic investments.

Their debt-to-equity ratio is a high 174.81%, indicating that the company has a significant amount of debt compared to its equity. This can be a concern for investors, but it's essential to consider the context and the company's overall financial health.

The company's levered free cash flow is a modest $23.63 million, which may not be sufficient to cover debt payments and other obligations. This could be a red flag for investors, especially if the company's debt burden is high.

Here's a summary of Cresco Labs' financial information:

Let's take a closer look at the company's financial position and cash flow.

The company's market capitalization is 404.70M, while its enterprise value is significantly higher at 889.00M.

The price-to-sales ratio is 0.58, which indicates that the company's stock price is relatively low compared to its revenue.

The total cash on hand is 146.61M, which is a substantial amount of liquidity for the company.

The company's debt-to-equity ratio is a staggering 174.81%, indicating a high level of leverage.

Here's a breakdown of the company's cash flow:

In terms of profitability, the company's profit margin is a concerning -6.74%. This means that for every dollar earned, the company is losing 6.74 cents.

The return on assets (ROA) is a more positive 4.13%, indicating that the company is generating a decent amount of profit from its assets. However, the return on equity (ROE) is a negative -9.89%, suggesting that the company's equity is not generating the expected returns.

Revenue has been steadily increasing, reaching $677.35 million in the most recent quarter.

Here's a breakdown of the company's income statement:

The company's net income available to common has taken a hit, coming in at -$45.68 million in the most recent quarter. This has resulted in a diluted EPS of -$0.1400, indicating a significant loss per share.

Cresco Labs had an annual revenue of $724.3 million in 2025.

A significant figure, to say the least. The financials of Cresco Labs are certainly impressive.

Their annual revenue was a notable $724.3 million in 2025, a substantial sum that reflects the company's growth and success.

Cresco Labs operates within a diverse range of industries, including agriculture, forestry, fishing, and hunting, as indicated by its NAICS code 42.

The company's operations also involve manufacturing, specifically the production of chemicals, plastics, and rubber, which is reflected in its NAICS code 325.

Cresco Labs is also involved in the wholesale trade of durable goods, as shown by its NAICS code 424.

This breadth of industries and operations suggests that Cresco Labs is a multifaceted company with a wide range of activities.

Worth a look: Bank Naics Code

Cresco Labs, Inc. is one of the largest vertically integrated, multi-state operators in the US.

Their mission is to normalize and professionalize the cannabis industry.

Headquartered in Chicago, Illinois, Cresco Labs has a significant presence in the US cannabis market.

They aim to make a positive impact through their operations and community involvement.

Drug manufacturers play a crucial role in the healthcare industry, producing both specialty and generic medications.

Specialty medications are often tailored to treat complex or rare conditions, and they can be extremely expensive, with prices ranging from $50,000 to $100,000 per year.

In contrast, generic medications are often significantly cheaper, with prices up to 90% lower than their branded counterparts.

Generic medications must meet the same quality and safety standards as their branded counterparts, and they are subject to rigorous testing and approval processes.

The generic drug market is a growing segment of the pharmaceutical industry, with sales projected to reach $1.4 trillion by 2025.

For more insights, see: The Importer Reported a Generic Error

The NAICS code is a six-digit number used by the US Census Bureau to classify businesses by industry.

It's a crucial tool for companies like Cresco Labs, which has NAICS codes 42, 32, 325, 3254, 32541, and 424.

The NAICS code helps businesses like Cresco Labs identify their industry and competitors.

NAICS codes are used for statistical purposes and to help businesses comply with regulations.

Companies can use their NAICS code to apply for government contracts and loans.

NAICS codes are also used to track economic trends and industry growth.

See what others are reading: Scalable Creative Solutions Large Businesses

Cresco Labs has SIC codes of 28, 283, 51, and 515.

These codes are used to classify the company's business activities.

The SIC code 28 is for chemicals and allied products.

Cresco Labs operates in a specific industry, which is reflected in its SIC codes.

The code 283 is for pharmaceuticals.

These codes provide a standardized way to identify the company's business.

The SIC code 51 is for printing and publishing.

This classification is useful for regulatory and financial purposes.

The code 515 is for tobacco products.

Understanding the SIC codes of Cresco Labs can be helpful for investors and researchers.

Intriguing read: 28 Dolar Kaç Türk Lirası

Cresco Labs is set to be one of Kentucky's largest medical marijuana facilities, with a reported $15.4 million facility expected to have products available by the end of the year.

The facility will have up to 25,000 square feet of growing capacity, making it one of just two facilities in the Commonwealth with such capacity.

You might enjoy: Lean Facility Management

Up to 100 full-time employees will be working at the Winchester location when the facility is fully operational.

Phase 1 of construction is anticipated for completion in August 2025.

Cresco Labs plans to keep the community informed about the facility's progress and operations.

The company has experience launching cannabis programs in other states, such as Illinois and Pennsylvania.

Intriguing read: West Point Mint Facility